Innate immune defense system of the skin

Veterinary Dermatology

Volumn 24, Issue 1, 2013, Pages

  Afshar, Maryam ^a   Gallo, Richard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; GENE EXPRESSION REGULATION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; SKIN;

ANIMALS; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; SKIN;

ANIMALIA; FUNGI; MAMMALIA;

EID: 84872692919     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01082.x     Document Type: Article

References (95)

1. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000; 343: 338-344.
2. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50-54.
3. Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000; 1: 141-150.
4. Bernard J, Gallo R. Protecting the boundary: the sentinel role of host defense peptides in the skin. Cell Mol Life Sci 2011; 68: 2189-2199.
5. Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009; 129: 1892-1908.
6. Proksch E, Brandner JM, Jensen J-M. The skin: an indispensable barrier. Exp Dermatol 2008; 17: 1063-1072.
7. Williams S, Brown T, Roghanian A et al. SLPI and elafin: one glove, many fingers. Clin Sci (Lond) 2006; 110: 21-35.
8. Zasloff M. Antimicrobial peptides in health and disease. N Engl J Med 2002; 347: 1199-1200.
9. Wang G, Epand RF, Mishra B et al. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37. Antimicrob Agents Chemother 2012; 56: 845-856.
10. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720.
11. Linde A, Ross CR, Davis EG et al. Innate immunity and host defense peptides in veterinary medicine. J Vet Intern Med 2008; 22: 247-265.
12. Wingate KV, Torres SM, Silverstein KAT et al. Expression of endogenous antimicrobial peptides in normal canine skin. Vet Dermatol 2009; 20: 19-26.
13. Ali RS, Falconer A, Ikram M et al. Expression of the peptide antibiotics human β defensin-1 and human β defensin-2 in normal human skin. J Invest Dermatol 2001; 117: 106-111.
14. Zeeuwen PLJM, Hendriks W, de Jong WW et al. Identification and sequence analysis of two new members of the SKALP/elafin and SPAI-2 gene family. J Biol Chem 1997; 272: 20471-20478.
15. Sang Y, Patil A, Zhang G et al. Bioinformatic and expression analysis of novel porcine β-defensins. Mamm Genome 2006; 17: 332-339.
16. Brown T, Mistry R, Gray R et al. Characterization of the ovine ortholog of secretory leukoprotease inhibitor. Mamm Genome 2005; 16: 621-630.
17. Zhao C, Nguyen T, Liu L et al. Gallinacin-3, an inducible epithelial β-defensin in the chicken. Infect Immun 2001; 69: 2684-2691.
18. Patil AA, Cai Y, Sang Y et al. Cross-species analysis of the mammalian β-defensin gene family: presence of syntenic gene clusters and preferential expression in the male reproductive tract. Physiol Genomics 2005; 23: 5-17.
19. Bruhn O, Grötzinger J, Cascorbi I et al. Antimicrobial peptides and proteins of the horse - insights into a well-armed organism. Vet Res 2011; 42: 98.
20. Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol 2011; 131: 1974-1980.
21. Aberg KM, Man M-Q, Gallo RL et al. Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 2007; 128: 917-925.
22. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
23. Jenssen H, Hamill P, Hancock R. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491-511.
24. Yeaman M, Yount N. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55: 27-55.
25. Henzler-Wildman KA, Martinez GV, Brown MF et al. Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry 2004; 43: 8459-8469.
26. Radek K, Gallo R. Antimicrobial peptides: natural effectors of the innate immune system. Semin Immunopathol 2007; 29: 27-43.
27. Kristian SA, Timmer AM, Liu GY et al. Impairment of innate immune killing mechanisms by bacteriostatic antibiotics. FASEB J 2007; 21: 1107-1116.
28. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30: 131-141.
29. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 2008; 122: 261-266.
30. Gallo RL, Ono M, Povsic T et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci U S A 1994; 8: 11035-11039.
31. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 2001; 117: 91-97.
32. Carman RL, Old JM, Baker M et al. Identification and expression of a novel marsupial cathelicidin from the tammar wallaby (Macropus eugenii). Vet Immunol Immunopathol 2009; 127: 269-276.
33. Santoro D, Bunick D, Graves TK et al. Expression and distribution of antimicrobial peptides in the skin of healthy beagles. Vet Dermatol 2011; 22: 61-67.
34. Leonard BC, Chu H, Johns JL et al. Expression and activity of a novel cathelicidin from domestic cats. PLoS One 2011; 6: e18756.
35. Braff MH, Nardo AD, Gallo RL. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 2005; 124: 394-400.
36. Santoro D, Marsella R, Bunick D et al. Expression and distribution of canine antimicrobial peptides in the skin of healthy and atopic beagles. Vet Immunol Immunopathol 2011; 144: 382-388.
37. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374: 1-5.
38. Zaiou M, Nizet V, Gallo R. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003; 120: 810-816.
39. Verbanac D, Zanetti M, Romeo D. Chemotactic and protease-inhibiting activities of antibiotic peptide precursors. FEBS Lett 1993; 317: 255-258.
40. Izadpanah A, Gallo RL. Antimicrobial peptides. J Am Acad Dermatol 2005; 52: 381-390.
41. Durr U, Sudheendra U, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 2006; 1758: 1408-1425.
42. Schauber J, Dorschner RA, Yamasaki K et al. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 2006; 118: 509-519.
43. Dorschner RA, Lin KH, Murakami M et al. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 2003; 53: 566-572.
44. Braff MH, Hawkins MiA, Di Nardo A et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005; 174: 4271-4278.
45. Murakami M, Lopez-Garcia B, Braff M et al. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004; 172: 3070-3077.
46. Dorschner RA, Lopez-Garcia B, Peschel A et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J 2006; 20: 35-42.
47. Frohm M, Agerberth B, Ahangari G et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272: 15258-15263.
48. Nagy I, Pivarcsi A, Kis K et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 2006; 8: 2195-2205.
49. Lee D-Y, Yamasaki K, Rudsil J et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill Propionibacterium acnes. J Invest Dermatol 2008; 128: 1863-1866.
50. Conner K, Nern K, Rudisill J et al. The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and verruca vulgaris. J Am Acad Dermatol 2002; 47: 347-350.
51. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
52. Howell MD, Jones JF, Kisich KO et al. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004; 172: 1763-1767.
53. Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. J Biol Chem 2006; 281: 1636-1643.
54. Yang D, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and Tcells. J Exp Med 2000; 192: 1069-1074.
55. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003; 170: 2274-2278.
56. Koczulla R, von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111: 1665-1672.
57. 2 production from mast cells. Eur J Immunol 2001; 31: 1066-1075.
58. Tokumaru S, Sayama K, Shirakata Y et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol 2005; 175: 4662-4668.
59. Scott MG, Rosenberger CM, Gold MR et al. An α-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J Immunol 2000; 165: 3358-3365.
60. Di Nardo A, Braff MH, Taylor KR et al. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J Immunol 2007; 178: 1829-1834.
61. Davidson DJ, Currie AJ, Reid GSD et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced Tcell polarization. J Immunol 2004; 172: 1146-1156.
62. van Damme CMM, Willemse T, van Dijk A et al. Altered cutaneous expression of β-defensins in dogs with atopic dermatitis. Mol Immunol 2009; 46: 2449-2455.
63. Yasui T, Fukui K, Nara T et al. Immunocytochemical localization of lysozyme and β-defensin in the apocrine glands of the equine scrotum. Arch Dermatol Res 2007; 299: 393-397.
64. Bagnicka E, Strzalkowska N, Jóźwik A et al. Expression and polymorphism of defensins in farm animals. Acta Biochim Pol 2010; 57: 487-497.
65. Leonard BC, Marks SL, Outerbridge CA et al. Activity, expression and genetic variation of canine β-defensin103: a multifunctional antimicrobial peptide in the skin of domestic dogs. J Innate Immun 2012; 4: 248-259.
66. Selsted ME, Harwig SS, Ganz T et al. Primary structures of three human neutrophil defensins. J Clin Invest 1985; 76: 1436-1439.
67. Sang Y, Ortega MT, Blecha F et al. Molecular cloning and characterization of three β-defensins from canine testes. Infect Immun 2005; 73: 2611-2620.
68. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389-406.
69. Harder J, Bartels J, Christophers E et al. A peptide antibiotic from human skin. Nature 1997; 387: 861.
70. Nomura I, Goleva E, Howell MD et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003; 171: 3262-3269.
71. Gallo RL, Murakami M, Ohtake T et al. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002; 110: 823-831.
72. Froy O. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell Microbiol 2005; 7: 1387-1397.
73. Lai Y, Cogen AL, Radek KA et al. Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections. J Invest Dermatol 2010; 130: 2211-2221.
74. Butmarc J, Yufit T, Carson P et al. Human β-defensin-2 expression is increased in chronic wounds. Wound Repair Regen 2004; 12: 439-443.
75. Nakatsuji T, Kao MC, Zhang L et al. Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating β-defensin-2 expression. J Invest Dermatol 2010; 130: 985-994.
76. Zaalouk TK, Bajaj-Elliott M, George JT et al. Differential regulation of β-defensin gene expression during Cryptosporidium parvum infection. Infect Immun 2004; 72: 2772-2779.
77. Yadava P, Zhang C, Sun J et al. Antimicrobial activities of human β-defensins against Bacillus species. Int J Antimicrob Agents 2006; 28: 132-137.
78. Kisich K, Howell M, Boguniewicz M et al. The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on β-defensin3. J Invest Dermatol 2007; 127: 2368-2380.
79. García J-R, Jaumann F, Schulz S et al. Identification of a novel, multifunctional β-defensin (human β-defensin3) with specific antimicrobial activity. Cell Tissue Res 2001; 306: 257-264.
80. Befus AD, Mowat C, Gilchrist M et al. Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol 1999; 163: 947-953.
81. Yang D, Chertov O, Bykovskaia SN et al. Beta-defensins: linking innate and adaptive immunity through dendritic and Tcell CCR6. Science 1999; 286: 525-528.
82. Niyonsaba F, Ushio H, Nakano N et al. Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 2007; 127: 594-604.
83. Candille SI, Kaelin CB, Cattanach BM et al. A β-defensin mutation causes black coat color in domestic dogs. Science 2007; 318: 1418-1423.
84. Schittek B, Hipfel R, Sauer B et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol 2001; 2: 1133-1137.
85. Senyurek I, Paulmann M, Sinnberg T et al. Dermcidin-derived peptides show a different mode of action than the cathelicidin LL-37 against Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2499-2509.
86. Regenhard P, Petzl W, Zerbe H et al. The antibacterial psoriasin is induced by E. coli infection in the bovine udder. Vet Microbiol 2010; 143: 293-298.
87. Glaser R, Harder J, Lange H et al. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2004; 6: 57-64.
88. White SD. Advances in equine atopic dermatitis, serologic and intradermal allergy testing. Clin Tech Equine Pract 2005; 4: 311-313.
89. Reedy LM. Results of allergy testing and hyposensitization in selected feline skin diseases. J Am Anim Hosp Assoc 1982; 18: 618-623.
90. Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy. Vet Immunol Immunopathol 2001; 81: 311-316.
91. Leung DYM, Boguniewicz M, Howell MD et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-657.
92. Howell MD, Gallo RL, Boguniewicz M et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006; 24: 341-348.
93. Howell MD, Wollenberg A, Gallo RL et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.
94. Hata TR, Kotol P, Boguniewicz M et al. History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol 2010; 163: 659-661.
95. Prado-Montes de Oca E, García-Vargas A, Lozano-Inocencio R et al. Association of β-defensin1 single nucleotide polymorphisms with atopic dermatitis. Int Arch Allergy Immunol 2007; 142: 211-218.